	US 7,589,097 B2
	Triazol[4,5-d] pyramidine derivatives and their use as purinergic receptor antagonists
Roger John Gillespie, Wokingham (United Kingdom); Joanne Lerpiniere, Wokingham (United Kingdom); Suneel Gaur, Wokingham (United Kingdom); Samantha Jayne Bamford, Wokingham (United Kingdom); Gemma Caroline Stratton, Wokingham (United Kingdom); Stefania Leonardi, Workingham (United Kingdom); and Scott Murray Weiss, Wokingham (United Kingdom)
Assigned to Vernalis Research Limited, Wokingham (United Kingdom)
Filed on Dec. 20, 2007, as Appl. No. 12/3,110.
Application 12/003110 is a division of application No. 11/507625, filed on Aug. 22, 2006, granted, now 7,405,219.
Application 11/507625 is a continuation of application No. 10/250942, granted, now 7,141,575, previously published as PCT/GB02/00091, filed on Jan. 10, 2002.
Claims priority of application No. 0100624.6 (GB), filed on Jan. 10, 2001.
Prior Publication US 2008/0234296 A1, Sep. 25, 2008
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/519 (2006.01); A61P 25/16 (2006.01); A61P 9/02 (2006.01); A61P 25/02 (2006.01); A61P 25/14 (2006.01); A61P 25/18 (2006.01); A61P 25/28 (2006.01)

U.S. Cl. 514—261.1 [544/254]

2 Claims

1. A method of treating a patient suffering from Parkinson's disease comprising administering to the patient an effective dose of a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof,

at least one additional drug useful in the treatment of Parkinson's disease and

at least one pharmaceutically acceptable carrier,

wherein

R₁is selected from the group consisting of H, alkyl, aryl, alkoxy, aryloxy, alkylthio, arylthio, halogen, CN, NR₅R₆, NR₄COR₅, NR₄CONR₅R₆, NR₄CO₂R₇and NR₄SO₂R₇;

R₂is an aryl attached via an unsaturated ring carbon of said aryl group;

R₃is selected from the group consisting of H, alkyl, COR₅, CO₂R₇, CONR₅R₆, CONR₄NR₅R₆and SO₂R₇;

R₄, R₅and R₆are independently selected from the group consisting of H, alkyl and aryl, or where R₅and R₆are in an NR₅R₆group, R₅and R₆may be linked to form a heterocyclic group, or where R₄, R₅and R₆are in a (CONR₄NR₅R₆) group, R₄and R₅may be linked to form a heterocyclic group; and

R₇is selected from the group consisting of alkyl and aryl.